Eli Lilly is targeting an FDA submission for retatrutide in late 2026, after the largest of its Phase 3 trials are published
It is also about the habits built during the process
See our Privacy Policy for full details, or read more about our approach to data, science, and privacy on our Science page
Peters SAE, Woodward M (2018) Sex differences in the burden and complications of diabetes
This regulatory milestone arrives as consumer search interest for weight loss medications often increases around the New Year period
A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot program that would touch hundreds of lives: It started covering obesity drugs for state employeeseven as many other insurers balked at what they considered expensive vanity drugs